促血小板生成素通过METTL16/Akt信号改善化疗诱导血小板减少症血液病患者骨髓内皮祖细胞功能
本研究探讨促血小板生成素(TPO)对化疗诱导血小板减少症(CIT)血液病患者骨髓内皮祖细胞(BM EPCs)恢复的作用及机制。体外实验显示TPO显著改善CIT患者BM EPCs的数量和功能,并恢复血管缺陷斑马鱼的肠下静脉面积;机制上TPO通过METTL16介导的Akt信号增强BM EPC功能,METTL16在CIT患者BM EPCs中下调并参与内皮功能调控。
要点
- TPO显著改善CIT患者BM EPCs的体外数量和功能。
- TPO通过METTL16介导的Akt信号增强BM EPC功能。
- METTL16在CIT患者BM EPCs中下调并参与内皮功能调控。
核心结论
- TPO通过METTL16/Akt信号改善血液系统恶性肿瘤CIT患者BM EPCs的恢复,为TPO治疗CIT提供除直接巨核细胞生成外的新见解。
研究设计与样本
- 研究采用CIT患者BM EPCs进行体外功能实验,并以血管缺陷斑马鱼作为体内模型。
- 内皮细胞转染METTL16慢病毒后进行甲基化RNA免疫沉淀测序。
主要发现
- TPO显著改善CIT患者BM EPCs的体外数量和功能。
- TPO恢复血管缺陷斑马鱼肠下静脉面积。
- TPO通过METTL16介导的Akt信号增强BM EPC功能。
- METTL16在CIT患者BM EPCs中下调并参与内皮功能调控。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Bone marrow endothelial progenitor cells (BM EPCs) are crucial in supporting haematopoietic regeneration, while the BM EPCs of haematological patients with chemotherapy-induced thrombocytopenia (CIT) are unavoidably damaged. Therefore, the present study aimed to examine the effect of thrombopoietin (TPO) on the recovery of BM EPCs of CIT patients and to identify the underlying mechanisms. The cell functions were determined by 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate (Dil)-acetylated low-density lipoprotein (Dil-Ac-LDL) uptake and fluorescein isothiocyanate (FITC)-labeled Ulex europaeus agglutinin-I (FITC-UEA-I) binding assay, as well as proliferation, migration and tube formation experiments. Endothelial cells were transfected with METTL16 lentivirus, followed by methylated RNA immunoprecipitation sequencing. Zebrafish with vascular defect was used as the in vivo model. TPO significantly improved the quantity and functions of BM EPCs from CIT patients in vitro and restored the subintestinal vein area of zebrafish with vascular defect in vivo. Mechanically, TPO enhanced the BM EPC functions through Akt signal mediated by METTL16, which was downregulated in BM EPCs of CIT patients and involved in the regulation of endothelial functions. The present study demonstrates that TPO improves the recovery of BM EPCs from CIT patients with haematological malignancies via METTL16/Akt signalling, which provides new insights into the role of TPO in treating CIT in addition to direct megakaryopoiesis.
引用
- Chen H, Jiao Y, Lin C, et al. Thrombopoietin improves the functions of bone marrow endothelial progenitor cells via METTL16/Akt signalling of haematological patients with chemotherapy-induced thrombocytopenia. Br J Haematol. 2024. PMID: 39189039. doi:10.1111/bjh.19722
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。